Michael Poisel

Director at Linnaeus Therapeutics.

Earliest Form D on file: Aug 2025

5 filings at 1 company

Linnaeus Therapeutics

Haddonfield NJ

Director

Haddonfield NJ

Signed
Named
AmendmentAmendment of an earlier filing
Size is amount sold, up to $30M

Filings

5 filings · 2 offerings

Feb 27, 2026
Equity, named · Form D
$4.992M
of $10M
Feb 27, 2026
Latest Apr 2, 2026
Equity
Named, Director
$4.992M
$10M
Form D
3 amendmentsLatest Apr 2, 2026
- Apr 2, 2026$4.992MForm D
  Apr 2, 2026$4.992MForm D
- Mar 31, 2026$4.892MForm D
  Mar 31, 2026$4.892MForm D
- Mar 13, 2026$4.792MForm D
  Mar 13, 2026$4.792MForm D
Aug 22, 2025
Debt, security to be acquired, named · Form D
$1.275M
of $10M
Aug 22, 2025
Debt, security to be acquired
Named, Director
$1.275M
$10M
Form D

Network

At Linnaeus Therapeutics

6 people

Patrick T. Mooney
Together on 5 filings
Executive Officer, Director
Chris Arendt
Together on 5 filings
Director
James Demetriades
Together on 5 filings
Director
Todd T. Thomson
Together on 5 filings
Director
John Lepping
Together on 4 filings
Director
Jack Lepping
Together on 1 filing
Director